This is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with ALK+ non-small cell lung cancer as seen in clinical practice. The hypothetical case was co-developed by staff Medical Writers with Cancer Network/ONN

Medical experts discuss strategies for managing adverse events associated with KRAS-targeted therapies, addressing monitoring challenges with oral medications and balancing symptom management with treatment efficacy.

The role of oncology nurses and APPs in research is largely to stay abreast of trials that may be useful to patients and recommend them whenever possible, according to Erica Doubleday, MS, FNP-C, BSN, RN.

Proactive onco-coaching did not improve QOL but was associated with improved OS in patients with metastatic renal cell carcinoma receiving TKIs and ICIs.

Patients treated with tyrosine kinase inhibitors received olanzapine to address adverse effects including nausea/vomiting, anorexia, insomnia, and weight loss.

Patients with recurrent/metastatic HER2-positive breast cancer experienced durable response and manageable safety from KN026-docetaxel combination therapy.

Lisocabtagene maraleucel demonstrated a statistically significant overall response rate in adults with relapsed/refractory marginal zone lymphoma.

New results uphold previous findings regarding the efficacy of cabozantinib, nivolumab, and ipilumumab arm for advanced renal cell carcinoma.

Patients with advanced RCC who were treated with nivolumab plus cabozantinib had a median PFS of 16.4 months compared with 8.3 months from sunitinib alone.

Men with intermediate-risk prostate cancer and high PSA levels before HIFU treatment had a greater risk of both overall recurrence and treatment failure.

Enfortumab vedotin alone and in combination with pembrolizumab showed promise in patients with upper tract urothelial carcinoma, particularly those ineligible for standard chemotherapy.

Real-world data demonstrate significant outcome improvements with enfortumab vedotin in patients with unresectable or metastatic urothelial carcinoma.

Patients with metastatic hormone-sensitive prostate cancer experienced increase rPFS and other efficacy end points with darolutamide plus ADT.

Improved progression-free survival in metastatic urothelial carcinoma was observed in patients experiencing neuropathy, skin rash, and hyperglycemia following enfortumab vedotin.

Increase in QOL and decrease in sexual function are among the benefits and risks, respectively, of adding SADT to EBRT for intermediate-risk prostate cancer.

Findings also suggested that an up-front dose reduction of enfortumab vedotin may benefit older patients with urothelial carcinoma.

MyCareGorithm was met with high approval from patients, companions, and physicians, with all 3 groups reporting they’d recommend the tool to other patients.

Dr Mohan discusses with Nurse Goff, Dr Mohan, and Dr Nadeem strategies for maintaining continuity of care and communication between community centers and academic institutions during bispecific therapy, as well as best practices for transitioning care back to the community center after therapy administration.

Dr Mohan discusses with Dr Nadeem, Dr Mann, and Nurse Distaso the key factors for referring patients from community centers to academic institutions for bispecific therapy and strategies for effectively initiating these discussions with patients.

While lower relative dose intensity of docetaxel was associated with higher rates of G-CSF use and more adverse events, discontinuation rates were low across all groups.

Patients with mCRPC taking LuPSMA had a median OS of 34 months vs 26 months with enzalutamide alone.

With delays in biomarker testing and treatment for metastatic castration-resistant prostate cancer, continued education is needed to address these gaps.

Nurses and APPs provide an essential link between physicians and patients when facilitating and monitoring outcomes with personalized cancer vaccines.

Patients with HRR-deficient metastatic castration-resistant prostate cancer saw a 14-month boost in OS and a 38% lower risk of death with talazoparib plus enzalutamide.